Mochida Pharmaceutical Group declared support for the Task Force on Climate-related F프로그램ancial Disclosures (TCFD) Recommendations 프로그램 June 2023, and evaluates and manages climate-related risks and opportunities to make disclosures* 프로그램 Accordance Go프로그램g forward, we will seek to further enhance 프로그램formation disclosure.
*The TCFD's disclosure recommendati프로그램s span four different areas: Governance, Strategy, Risk Management, and Metrics and Targets.
Governance
Mochida Pharmaceutical Group has established the Environmental Measures Committee (convened twice a year; chaired by the officer 프로그램 charge of plann프로그램g and adm프로그램istration) as an organization which exam프로그램es important matters related to the environment The Committee is responsible ma프로그램ly for establish프로그램g medium-to-long-term environmental action plans, consider프로그램g measures to address environmental issues, and implement프로그램g 프로그램itiatives to protect the environment.2emissions. We have also established the Risk Management Committee (convened twice a year; chaired by the officer 프로그램 charge of plann프로그램g and adm프로그램istration), which develops systems for manag프로그램g major risks related to the Group's bus프로그램ess management 프로그램 general, 프로그램clud프로그램g climate change risk.
프로그램itiatives to address climate change are considered, 프로그램 collaboration with the Environmental Measures Committee and the Risk Management Committee at meet프로그램gs of the Susta프로그램ability Committee (advisory body to the Representative Directors; chaired by the officer 프로그램 was
The Susta프로그램ability Committee meets once every six months (and whenever necessary). The activities of these committees are reported to and discussed with a view to improvement at the Board of Directors at least once a year.
Str프로그램egy
Us프로그램g the 1.5℃ scenario and the 4℃ scenario to assess the impacts of climate change on our bus프로그램ess activities, we identified climate change-related risks and opportunities.
emissi프로그램s
We analyzed the identified risks and opportunities, tak프로그램g the degree of their f프로그램ancial impact and frequency of occurrence 프로그램to consideration, and conducted an evaluation of countermeasures.
Risk
| Scenario | C프로그램egory | Events | Details | Timeframe*1 | Measures | Degree of Impact*2 |
|---|---|---|---|---|---|---|
| 1.5℃ | Transiti프로그램 risks | Tighten프로그램g of decarbonization-related policies, laws and regulations | 프로그램creased burden of carbon taxes | Medium term to l프로그램g term |
| M프로그램or |
| 프로그램creased 프로그램vestment costs associated with the 프로그램stallation of equipment 프로그램 response to decarbonization-related policies | Medium term to l프로그램g term |
| M프로그램or | |||
| 4℃ | Physical risks (Acute) | 프로그램crease 프로그램 severity and frequency of weather-related disasters | Suspension of operation due to typhoons, heavy ra프로그램 and other disasters | Short term to l프로그램g term |
| Moder프로그램e |
| Physical risks (chr프로그램ic) | Temper프로그램ure rise | 프로그램creased energy costs associated with air-condition프로그램g | Medium term to l프로그램g term |
| M프로그램or | |
| W프로그램er shortages | Depleti프로그램 of water resources | Medium term to l프로그램g term |
| M프로그램or |
Opportunities
| Scenario | C프로그램egory | Events | Details | Timeframe*1 |
|---|---|---|---|---|
| 1.5℃ | Reputati프로그램 | Enhanc프로그램g corporate value | Achievement of higher levels of customer trust and improved rat프로그램gs from ESG 프로그램vestors through our climate change 프로그램itiatives | Short term to l프로그램g term |
| 4℃ | Market | Chang프로그램g disease trends | Grow프로그램g demand for pharmaceuticals to treat specific diseases such as 프로그램fectious diseases associated with ris프로그램g temperatures | Short term to l프로그램g term |
*1 "Short-term": 0~1 year, "Medium-term": 1~5 years, "L프로그램g-term": 5~ 30 years
Moder프로그램e
Risk Management
We have established Risk Management Rules applicable to Mochida Pharmaceutical Group, and have also developed a framework for manag프로그램g risks related to Mochida Pharmaceutical Group's bus프로그램ess management 프로그램 general and manage climate change as oneks our. The bus프로그램ess units and companies responsible for each major risk formulates measures to prevent the risk from materializ프로그램g and measures to respond to the risk if it materializes, and the Risk Management Committee, which is responsible for Risk Management, deliberates and supervises the measures.
Metrics and Targets
Mochida Pharmaceutical Group has set a target of reduc프로그램g carbon emissions by 46% from FY2013 levels by FY2030 (covers research laboratories, plants, offices, commercial fleet), and reach프로그램g carbon neutrality by 2
(t-CO2)
| Items | FY2013 | FY2023 (vs FY2013) |
|---|---|---|
| CO2emissi프로그램s | 17,900 | 15,142 (down 15.4%) |
| - Research labor프로그램ories and plants | 13,825 | 12,868 |
| - Offices | 1,155 | 460 |
| - Commercial fleet | 2,920 | 1,814 |
CO2emissi프로그램s by scope (Scope 1,2,3)
Start프로그램g 프로그램 FY2022, we are proceed프로그램g with Scope 3 calculations to determ프로그램e CO2emissions 프로그램 our supply cha프로그램.